Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
Winer, E
Batist, G
Harris, L
Hooftman, L
Park, Y
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Liposome Co, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59O
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Sofyan M. Radaideh
    George W. Sledge
    Breast Cancer Research and Treatment, 2008, 111 : 203 - 208
  • [22] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Radaideh, Sofyan M.
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (02) : 203 - 208
  • [23] Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study
    Lorusso, V.
    Giotta, F.
    Bordonaro, R.
    Maiello, E.
    Del Prete, S.
    Gebbia, V.
    Filippelli, G.
    Pisconti, S.
    Cinieri, S.
    Romito, S.
    Riccardi, F.
    Forcignano, R.
    Ciccarese, M.
    Petrucelli, L.
    Saracino, V.
    Lupo, L. I.
    Gambino, A.
    Leo, S.
    Colucci, G.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (05) : 2137 - 2142
  • [24] Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer (MBC): A National Cancer Institute of Canada (NCIC) study
    Khoo, K
    Brandes, L
    Reyno, L
    Dent, S
    Vandenberg, T
    Lebwohl, D
    Fisher, B
    Eisenhauer, E
    ANNALS OF ONCOLOGY, 1998, 9 : 171 - 171
  • [25] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer MBC
    Bensalem, A
    Bouzid, K
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 1) : S21 - S21
  • [26] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
    A Bensalem
    K Bouzid
    Breast Cancer Research, 7
  • [27] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [28] Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer
    Xu, Gaoqi
    Yang, Dihong
    He, Chaoneng
    Zhong, Like
    Zhu, Junfeng
    Shu, Qi
    Ding, Haiying
    Xin, Wenxiu
    Tong, Yinghui
    Zhu, Xiao
    Fang, Luo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (03) : 181 - 192
  • [29] A phase III randomized trial of doxorubicin (A) and docetaxel (D) versus doxorubicin and paclitaxel (P) in metastatic breast cancer - preliminary results of the Erasme 3 study
    Cassier, PA
    Chabaud, S
    Freyer, G
    Peaud, PY
    Tigaud, JD
    Cure, H
    Ofeuvre, H
    Salles, B
    Martin, C
    Jacquin, JP
    Agostini, C
    Bachelot, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S279 - S279
  • [30] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 study
    Cassier, Philippe A.
    Chabaud, Sylvie
    Trillet-Lenoir, Veronique
    Peaud, Pierre-Yves
    Tigaud, Jean-Dominique
    Cure, Herve
    Orfeuvre, Hubert
    Salles, Bruno
    Martin, Claude
    Jacquin, Jean-Philippe
    Agostini, Cecile
    Guastalla, Jean-Paul
    Perol, David
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350
12345